In this symposium, an expert panel will discuss cytomegalovirus (CMV) treatment guidelines and benefits and toxicities of traditional CMV therapies in hematopoietic cell transplant (HCT) patients. Panelists will address special challenges associated with refractory or drug-resistant CMV in HCT and present a new treatment option. An experienced patient with CMV will share impactful insights to help provide better care for HCT patients with CMV.
Hybrid Satellite Symposium, Attend in-person or virtually.
EBMT in Paris, France
Upon successful completion of this educational activity, participants should be better able to:
Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, United States
Head, Department of Hematology and Transplantation Programme
Hospital Universitario Puerta de Hierro Majadahonda
Profesor Asociado de Hematología
Universidad Autónoma de Madrid
Madrid, Spain
Professor, Virology
Limoges University Hospital
Research Leader, RESINFIT Inserm Team
Limoges University
Limoges, France
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources